Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Bone age less than or equal to (\</=) 8 years (females) or \</= 10 years (males) as determined by x-ray of the left hand and wrist obtained within six months before enrollment~* Prepubertal males and females by physical exam~* Naive to rhGH therapy~* Diagnosis of IGHD or ISS by standard pharmacologic testing and no other discernable etiology for short stature~* Height standard deviation score (Ht SDS) \</= -1.5 (\</= 5th percentile) for IGHD participants; Ht SDS \</= -2.25 (\</= 1.2 percentile) for ISS participants~Exclusion Criteria:~* Short stature etiologies other than IGHD or ISS~* Participants receiving chronic corticosteroid therapy (greater than \[\>\] 3 months) for other medical conditions~* Participants with active malignancy or any other condition that the investigator believes would pose a significant hazard to the participant if rhGH were initiated~* Females with turner syndrome~* Any previous rhGH treatment~* Participation in another simultaneous medical investigation or trial~* Pediatric participants with closed epiphyses~* Participants prescribed rhGH doses outside the variance of NCGS control participant dosing

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: IGHD participants (Type: None): Isolated growth hormone deficient (IGHD) participants who initiated somatropin (Deoxyribonucleic acid \[DNA\] origin) (recombinant human growth hormone \[rhGH\]) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
- Cohort 2: ISS participants (Type: None): Idiopathic short stature (ISS) participants who initiated somatropin (DNA origin) (rhGH) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).